Elon Musk, the controversial CEO of Tesla Inc., has raised eyebrows once again by suggesting that his prescribed use of ketamine is beneficial for investors in the company. In a surprising statement, Musk claimed that the use of the drug helps alleviate periods of low mood, ultimately benefiting Tesla shareholders.
This revelation comes on the heels of disappointing first-quarter delivery numbers from Tesla, which sent the company’s shares tumbling. Tesla sold just under 387,000 vehicles in the first quarter, falling short of Wall Street’s expectations and marking the company’s first year-over-year sales drop since the early days of the COVID-19 pandemic.
Analysts have described the figures as “an unmitigated disaster” and warned of potential challenges ahead for the electric car company. Despite the setbacks, Tesla managed to outsell Chinese automaker BYD Co. in the first quarter, reclaiming its title as the world’s largest EV seller.
The decline in Tesla’s delivery numbers has been attributed to various factors, including production ramp-ups for the updated Model 3, factory shutdowns due to external conflicts, and a decrease in consumer demand. Additionally, Musk’s controversial behavior on social media has been cited as a contributing factor to the shrinking number of would-be Tesla buyers in the U.S.
As Tesla faces mounting challenges and scrutiny, Musk’s unconventional methods and statements continue to draw attention and raise questions about their impact on the company’s performance and reputation.
